Sein métastatique RH+ SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer Paris, Saint-Cloud
Sein Néoadjuvant ULTIMATE A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant Paris, Saint-Cloud PAUL-HENRI COTTU, ETIENNE BRAIN
Sein métastatique RH+ PALATINE - UC-0140/1814 ADVANCED BREAST CANCER: THERAPY INTEGRATING LOCOREGIONAL TREATMENT IN DE NOVO,;TREATMENT NAIVE, STAGE IV ER+, HER2- BREAST CANCER PATIENTS RECEIVING LETROZOLE AND;PALBOCICLIB Paris, Saint-Cloud
Appareil Digestif REGIRI (PRODIGE 58) A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas Paris, Saint-Cloud
Appareil Digestif DS8201-A-U207 DESTINY CRC02 A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02) Saint-Cloud
Appareil Digestif TEDOPaM Prodige 63 A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study). Saint-Cloud
Appareil Digestif ProActIF-01 ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers Paris, Saint-Cloud
Appareil pulmonaire IONESCO (IFCT-1601) A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer. Saint-Cloud MARIE ANGE MASSIANI
Sein métastatique triple négatif TOPOLOGY A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Sein métastatique RH+ AIPAC AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel Saint-Cloud ETIENNE BRAIN